Vascular anomalies hemangioma, vascular anomalies
Conditions
Interventions
None listed
Sponsors
Michio Ozeki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1, A multicenter phase III investigator-initiated clinical trial (NPC-12T-LM study) conducted from 2017 to 2019 to investigate the efficacy and safety of NPC-12T (sirolimus) for intractable lymphatic disease, Multi-center, open-label, uncontrolled study to investigate the safety and efficacy of sirolimus for refractory vascular and lymphatic diseases (SRL-CVA-01 study, jRCTs031180290) started in 2017, and Conducted from 2020 to 2022, a multicenter phase III investigator-initiated clinical trial (NPC -12T-CVA) 2) Patients with evaluable MRI images 3) Patients who agreed to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients with other than obvious vascular abnormalities 2) Patients with clearly different lesions and image artifacts such as bleeding and inflammation that are difficult to evaluate 3) Other patients who are judged to be inappropriate by the principal investigator or co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation coefficient between "lesion volume of vascular abnormalities measured by deep learning" and "lesion volume independently measured by two radiologists" | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation coefficient (ICC(2,1)) of analysis results of area and volume measured independently by two radiologists and a trained doctor Differences in AI segmentation and correlation coefficients with different MRI images (fat-suppressed T2-weighted images, T1-weighted images, contrast-enhanced T1-weighted images, etc.) | — |
Contacts
Public ContactOzeki Michio
Gifu University Hospital
Outcome results
None listed